Cyfuse Biomedical KK
TSE:4892
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
451
1 320
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
C
|
Cyfuse Biomedical KK
TSE:4892
|
6.1B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
233.5B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
166.5B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.9T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.9B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.1B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
Cyfuse Biomedical KK
Glance View
Cyfuse Biomedical KK develops and manufactures cell regenerative systems. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2022-12-01. The firm is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The firm is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The firm is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Cyfuse Biomedical KK is -1 018.4%, which is above its 3-year median of -1 097.7%.
Over the last 3 years, Cyfuse Biomedical KK’s Operating Margin has decreased from -113.5% to -1 018.4%. During this period, it reached a low of -1 645.9% on Dec 31, 2024 and a high of -113.5% on Dec 1, 2022.